Victor Alan Levin

Victor Alan Levin's AcademicInfluence.com Rankings

Victor Alan Levin

Philosophy

#6667

World Rank

#9738

Historical Rank

Logic

#3800

World Rank

#5010

Historical Rank

philosophy Degrees

Victor Alan Levin

Biology

#9037

World Rank

#12194

Historical Rank

Neuroscience

#1298

World Rank

#1343

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Victor Alan Levin's Degrees

Doctorate Medicine University of California, San Francisco
PhD Neuroscience University of California, San Francisco

Why Is Victor Alan Levin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Victor Alan Levin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse (2000) (932)
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. (1999) (901)
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo (2000) (766)
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. (1999) (654)
Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. (2000) (590)
Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. (2011) (561)
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 (2006) (428)
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. (2000) (420)
The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT‐G) in patients with primary brain tumors (1995) (419)
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. (1990) (399)
Effect of bevacizumab on radiation necrosis of the brain. (2007) (370)
Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. (1998) (349)
Biology and treatment of malignant glioma. (2000) (274)
Reoperation for recurrent glioblastoma and anaplastic astrocytoma. (1987) (253)
Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. (1996) (251)
Cognitive function as a predictor of survival in patients with recurrent malignant glioma. (2000) (251)
Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. (2002) (214)
PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. (1988) (200)
Sucrose and inulin space measurements of cerebral cortex in four mammalian species. (1970) (199)
Cerebrospinal Fluid Production by the Choroid Plexus and Brain (1971) (198)
Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. (1987) (195)
Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources. (1984) (195)
External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. (1991) (188)
Differentiation of Cerebral Radiation Necrosis from Tumor Recurrence by [18F]FDG and 82Rb Positron Emission Tomography (1987) (185)
Overexpression of E2F‐1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo (1998) (179)
The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells (2000) (176)
Permeability characteristics of brain adjacent to tumors in rats. (1975) (174)
Polymorphisms of DNA Repair Genes and Risk of Glioma (2004) (172)
Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy. (1991) (170)
Increased levels of p21WAF1/Cip1 in human brain tumors. (1995) (160)
Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment (1996) (159)
Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas (1988) (154)
Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. (1997) (139)
External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the M. D. Anderson Cancer Center (1997) (138)
Prognostic implications of the proliferative potential of low-grade astrocytomas. (1988) (137)
Germline p53 gene mutations in subsets of glioma patients. (1994) (127)
Differential expression of two types of the neurofibromatosis type 1 (NF1) gene transcripts related to neuronal differentiation. (1991) (122)
Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. (1979) (120)
Hyperfractionated radiation therapy for brain-stem glioma: a phase I-II trial. (1989) (120)
Central nervous system cancers: Clinical Practice Guidelines in Oncology. (2005) (117)
Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. (1985) (116)
Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. (1996) (115)
Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation★ (2006) (112)
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma (2008) (108)
Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey. (1978) (108)
Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. (2003) (106)
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. (2012) (106)
Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. (1987) (102)
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. (1979) (101)
Neuronal cell differentiation of human neuroblastoma cells by retinoic acid plus herbimycin A. (1988) (101)
Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. (1991) (99)
Management of hypothalamic gliomas in children: an analysis of 33 cases. (1990) (95)
Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. (1996) (94)
Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential (2007) (92)
The treatment of anaplastic oligodendrogliomas and mixed gliomas. (1993) (91)
Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. (1998) (90)
Imaging patterns of multifocal gliomas. (1993) (89)
The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. (1997) (88)
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. (2000) (87)
γ-Radiation Sensitivity and Risk of Glioma (2001) (87)
Glutathione S-Transferase Polymorphisms and Survival in Primary Malignant Glioma (2004) (87)
The relationship of polyamines in cerebrospinal fluid to the presence of central nervous system tumors. (1976) (87)
Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. (1991) (86)
Potentiation of the antitumor therapeutic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor. (1981) (85)
The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU (1979) (84)
Chemotherapy of primary brain tumors. (1985) (83)
Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. (1995) (83)
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. (2002) (82)
Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors (1989) (81)
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. (2004) (79)
Activity of pp60c-src in 60 different cell lines derived from human tumors. (1994) (79)
Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines. (2010) (79)
Anaplastic Oligodendrogliomas: Prognostic Factors for Tumor Recurrence and Survival (2003) (76)
Predictive value of cerebrospinal fluid polyamines in medulloblastoma. (1979) (76)
Long-term Anti-inflammatory and Antihistamine Medication Use and Adult Glioma Risk (2008) (75)
Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. (1996) (74)
External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. (1998) (74)
Primary cerebral neuroblastoma. Long-term follow-up review and therapeutic guidelines. (1983) (72)
Hyperfractionated radiation therapy for gliomas of the brainstem in children and in adults. (1992) (72)
5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. (1984) (72)
Pharmacokinetics of BCNU in man: a preliminary study of 20 patients. (1978) (72)
Low-dose craniospinal radiation therapy for medulloblastoma. (1991) (71)
Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors. (1974) (68)
Extracellular space of the cerebral cortex of normothermic and hypothermic cats. (1970) (68)
13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. (2004) (68)
Treatment of recurrent gliomas with eflornithine. (1992) (66)
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. (1998) (66)
Csf polyamines: A new and important means of monitoring patients with medulloblastoma (1981) (64)
Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. (1992) (63)
Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. (1998) (63)
Hypofractionated radiotherapy for elderly or younger low-performance status glioblastoma patients: outcome and prognostic factors. (2003) (61)
Suppression of human glioma growth by adenovirus-mediated Rb gene transfer (1998) (61)
Supratentorial malignant gliomas of childhood. Results of treatment with radiation therapy and chemotherapy. (1984) (59)
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. (2015) (58)
Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine. (1988) (58)
2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: implications for management. (2003) (58)
Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. (1997) (58)
Heuristic modeling of drug delivery to malignant brain tumors (1980) (58)
Prognostic significance of p53 immunoreactivity in patients with glioma. (1995) (57)
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. (1995) (57)
Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status (2006) (57)
Response and progression in recurrent malignant glioma. (1999) (57)
Gamma-radiation sensitivity and risk of glioma. (2001) (57)
Mutagen sensitivity and risk of gliomas: a case-control analysis. (1996) (56)
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. (2008) (56)
Detection of cellular proteins that interact with the NF2 tumor suppressor gene product. (1994) (55)
Prognostic significance of the pretreatment CT scan on time to progression for patients with malignant gliomas. (1980) (55)
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. (1997) (53)
Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. (1999) (53)
Cancer in the nervous system (1996) (52)
Factors influencing the survival of rat brain tumor cells after in vitro treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea. (1975) (52)
Mutations of the p16 gene in gliomas. (1996) (51)
A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. (1999) (51)
Improvement in survival produced by sequential therapies in the treatment of recurrent medulloblastoma (1983) (51)
Modulation of Glioma Risk and Progression by Dietary Nutrients and Antiinflammatory Agents (2011) (50)
The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin) (1997) (50)
The uptake, distribution, and antitumor activity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the murine glioma. (1970) (49)
Final report on the united states phase i clinical trial of the hypoxic cell radiosensitizer, misonidazole (RO‐07‐0582; NSC #261037) (1981) (48)
Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. (1999) (48)
The treatment of brain stem and thalamic gliomas with 78 Gy of hyperfractionated radiation therapy. (1995) (47)
Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma (2015) (47)
Basis and importance of Src as a target in cancer. (2004) (47)
Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors. (1984) (47)
Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. (2002) (46)
Genetic polymorphisms in glutathione S-transferase mu and theta, N-acetyltransferase, and CYP1A1 and risk of gliomas. (1998) (46)
Quantitative observations of the acute effects of X-irradiation on brain capillary permeability: Part I (1979) (46)
Adjuvant chemotherapy for primary lymphoma of the central nervous system. (1990) (45)
Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme (2006) (45)
Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme (2009) (45)
Fenretinide activates caspases and induces apoptosis in gliomas. (1999) (44)
Brain-tumor chemotherapy. Pharmacological principles derived from a monkey brain-tumor model. (1977) (44)
MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas. (1995) (44)
The application of brain capillary permeability coefficient measurements to pathological conditions and the selection of agents which cross the blood-brain barrier (1976) (44)
Correlation between dynamic MRI and outcome in patients with malignant gliomas (1998) (44)
Phase I-II study of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors. (1987) (43)
Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine. (1989) (42)
Poorly differentiated gliomas of the cerebellum. A study of 18 patients (1990) (41)
A compartmental analysis of 24Na kinetics in rat cerebrum, sciatic nerve and cerebrospinal fluid (1972) (41)
Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. (2003) (40)
CNS Anticancer Drug Discovery and Development Conference White Paper. (2015) (39)
Physiological studies on the development of obstructive hydrocephalus in the monkey (1971) (39)
A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution. (1999) (39)
The concept of drug dose for in vitro studies with chemotherapeutic agents. (1978) (38)
Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors (2004) (37)
Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. (2000) (37)
Uptake and distribution of 3 H-methotrexate by the murine ependymoblastoma. (1972) (37)
Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab (2017) (37)
Cerebrospinal fluid polyamines in patients with Glioblastoma multiforme and anaplastic astrocytoma. (1980) (37)
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma (2013) (35)
Possible role of DT-diaphorase in the bioactivation of antitumor quinones. (1983) (35)
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma (2010) (34)
Correlation of p53 immunoreactivity and sequencing in patients with glioma (1996) (34)
Distribution of 5-fluorouracil-2- 14 C and its metabolites in a murine glioma. (1972) (33)
Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. (1998) (33)
Brain Tumor Working Group Report on the 9th International Conference on Brain Tumor Research and Therapy (1993) (32)
Primary central nervous system lymphoma: a role for adjuvant chemotherapy (1992) (32)
Northern California Oncology Group protocol 6G91: response to treatment with radiation therapy and seven-drug chemotherapy in patients with glioblastoma multiforme. (1986) (32)
Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module. (2010) (32)
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. (1996) (31)
Lipophilic drugs and lipoproteins: partitioning effects on chloroethylnitrosourea reaction rates in serum. (1980) (31)
Relationship of peripheral venous hematocrit to brain hematocrit. (1969) (30)
Analgesic activity of anticancer agent suramin (1992) (30)
An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting (2011) (29)
Blood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Challenges to Overcome (2020) (29)
Headache related to brain tumors (2006) (29)
Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. (1988) (29)
Management of brain metastases from breast carcinoma. (1993) (28)
Cysts in malignant gliomas (1980) (28)
Glutathione-dependent denitrosation of N,N'-bis(2-chloroethyl)N-nitrosourea (BCNU): nitrite release catalyzed by mouse liver cytosol in vitro. (1983) (28)
A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastoma. (2006) (28)
Pattern of recurrence of medulloblastoma after low-dose craniospinal radiotherapy (1993) (28)
Bioavailability of bromodeoxyuridine in dogs and toxicity in rats. (1985) (28)
Advances in gene therapy and immunotherapy for brain tumors (2003) (27)
Phase II evaluation of dibromodulcitol in the treatment of recurrent medulloblastoma, ependymoma, and malignant astrocytoma. (1984) (27)
A systematic approach to the management of patients with brain metastases of known or unknown primary site (2011) (27)
Biology and treatment of gliomas. (1992) (25)
High-Grade Gliomas: Diagnosis and Treatment (2007) (25)
Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricular 3-[(4-amino-2-methyl-5-pyrimidinyl)ethyl]-1-(2-chloroethyl)-1-nitro soureas and other nitrosoureas in beagles. (1985) (24)
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma (2011) (24)
Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas (2018) (24)
Role of bevacizumab therapy in the management of glioblastoma (2010) (24)
Neuro-oncology: an overview. (1999) (24)
Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-α (1992) (23)
The place of hydroxyurea in the treatment of primary brain tumors. (1992) (23)
Alternative splicing of neurofibromatosis type 1 gene transcript in malignant brain tumors: PCR analysis of frozen‐section mRNA (1992) (23)
Treatment of high-risk medulloblastoma and other primitive neuroectodermal tumors with reduced dose craniospinal radiation therapy and multi-agent nitrosourea-based chemotherapy. (1996) (23)
Drug delivery to CNS tumors. (1981) (22)
Ha-ras(val12) induces HSP70b transcription via the HSE/HSF1 system, but HSP70b expression is suppressed in Ha-ras(val12)-transformed cells. (2006) (22)
Prognostic significance of bromodeoxyuridine labeling in primary and recurrent glioblastoma multiforme. (1994) (21)
Analysis for 1,3-bis(2-chloroethyl)-1-nitrosourea by chemical ionization mass spectrometry. (1978) (21)
Quantitative observations of the acute effects of X-irradiation on brain capillary permeability: Part I. (1979) (21)
Controversies in the treatment of low-grade astrocytomas and oligodendrogliomas. (1996) (21)
Pattern of recurrence of medulloblastoma after low-dose craniospinal radiotherapy. (1994) (21)
In situ drug delivery. (1980) (20)
Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures (2012) (20)
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. (1986) (20)
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02 (2017) (19)
Inhibition of human glioblastoma cell growth by WAF1/Cip1 can be attenuated by mutant p53. (1995) (19)
Erratum: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system (International Journal of Radiation Oncology Biology Physics (2011) 79:5 (1487-95) DOI: 10.1016/j.ijrobp.2009.12.061) (2012) (19)
Retreatment of pediatric brain tumors with radiation and misonidazole: Results of a CCSG/RTOG phase I/II study (1986) (18)
Relationship of Octanol/Water Partition Coefficient and Molecular Weight to Cellular Permeability and Partitioning in S49 Lymphoma Cells (1984) (18)
Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy (2003) (18)
Ha-rasval12 induces HSP70b transcription via the HSE/HSF1 system, but HSP70b expression is suppressed in Ha-rasval12-transformed cells (2006) (18)
Clinical anticancer pharmacology: some pharmacokinetic considerations. (1986) (18)
Cyclooxygenase-2 Inhibitors in Glioma Therapy (2004) (18)
Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas (2007) (17)
Identification of allelic loss on chromosome arm 6p in human astrocytomas by arbitrarily primed polymerase chain reaction (1998) (17)
Increased chromosomal instability in peripheral lymphocytes and risk of human gliomas. (1999) (17)
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer (2014) (17)
A new treatment regimen for brainstem glioma: A pilot study of the brain tumor research center and childrens cancer study group (1986) (17)
A Phase II Trial of Oral Melphalan in Recurrent Primary Brain Tumors (1988) (16)
Bacterial expression of an active tyrosine kinase from a protein A/truncated c‐src fusion protein (1993) (16)
Relationship of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors (2004) (16)
Treatment of extraneural metastatic medulloblastoma with a combination of cyclophosphamide, adriamycin, and vincristine. (1988) (16)
A New Preclinical 3-Dimensional Agarose Colony Formation Assay (2008) (15)
Cysts in malignant gliomas. Identification by computerized tomography. (1980) (15)
Chemotherapeutic treatment of the diencephalic syndrome. A case report (1990) (15)
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma (2012) (14)
Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricularly administered bleomycin in beagles. (1985) (14)
Chapter 13 – CLINICAL PHARMACOLOGY OF THE NITROSOUREAS1 (1981) (14)
Gamma-ray mutagen sensitivity and survival in patients with glioma. (1998) (13)
Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia (2004) (13)
Dianhydrogalactitol (NSC-132313): pharmacokinetics in normal and tumor-bearing rat brain and antitumor activity against three intracerebral rodent tumors. (1976) (13)
Imidazole carboxamides: relationship of lipophilicity to activity against intracerebral murine glioma 26 and preliminary phase II clinical trial of 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in primary and secondary brain tumors. (1975) (13)
Posterior Fossa Decompression for Life-threatening Tonsillar Herniation in Patients with Gliomatosis Cerebri: Report of Three Cases (2003) (13)
Chapter 11:Clinical Applications of Polyamine-Based Therapeutics (2011) (13)
Methotrexate permeability and steady-state distribution in the murine ependymoblastoma. (1969) (12)
Chapter 20 – CHEMOTHERAPY OF RECURRENT BRAIN TUMORS1 (1981) (12)
Characterization of cellular pathways involved in glioblastoma response to the chemotherapeutic agent 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by gene expression profiling. (1999) (12)
Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors. (2001) (12)
Does chemotherapy benefit the patient with a central nervous system glioma? (1987) (12)
Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens (2004) (12)
Malignant supratentorial gliomas in childhood. (1987) (11)
Influence of acidic residues on substrate specificity of oncogene products pp60v-src and p56lck in vitro. (1992) (11)
Pharmacological principles of brain tumor chemotherapy. (1976) (11)
Putrescine diffusion in cat brain and capillary permeability in rat brain: relation to CSF putrescine levels in brain tumor patients. (1981) (11)
Understanding brain penetrance of anticancer drugs (2018) (11)
A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors (1988) (11)
Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients (2008) (11)
Detection of p21WAF1/Cip1 in brain metastases (2004) (10)
Modification of uptake and antiproliferative effect of methylglyoxal bis(guanylhydrazone) by treatment with alpha-difluoromethylornithine in rodent cell lines with different sensitivities to methylglyoxal bis(guanylhydrazone). (1985) (10)
CNS Anticancer Drug Discovery and Development: 2016 conference insights. (2017) (10)
Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015 (2003) (10)
Primary Cerebral Neuroblastomas (1981) (9)
Comparative pharmacokinetics of 1-(2-chloroethyl)-3-(2,6-dioxo-1-piperidyl)-1-nitrosourea in rats and patients and extrapolation to clinical trials. (1981) (9)
Differential splicing of the neurofibromatosis type-1 gene in the rat - splice variants homologous with the human are expressed in rat-cells. (1992) (9)
Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression‐free survival in patients treated with DFMO–PCV chemotherapy (2007) (9)
Phase II trial of topotecan (T) as a continuous intravenous infusion in patients (PTS) with high grade gliomas (1997) (9)
Induction of apoptosis by N-(4-hydroxyphenyl)retinamide in glioma cells. (1999) (9)
Brain, CSF, and tumor pharmacokinetics of α-difluoromethylornithine in rats and dogs (2004) (9)
Personalized medicine in neuro-oncology. (2016) (9)
Risk assessment for developing gliomas: a comparison of two cytogenetic approaches. (2001) (9)
Pineocytomas (1989) (8)
Tissue-based Assay for Ornithine Decarboxylase to Identify Patients Likely to Respond to Difluoromethylornithine (2004) (8)
Quantitative observations of the subacute effects of X irradiation on brain capillary permeability: Part II. (1979) (8)
Radiosensitization of the RIF-1 murine flank tumor by desmethylmisonidazole (Ro 05 9963) during interstitial brachytherapy. (1982) (7)
NCCN adult brain tumor practice guidelines. (1997) (7)
Potential antiglioma activity of 9-hydroxy-2-N-methylellipticine as determined by pharmacological and human tumor clonogenic cell studies. (1985) (7)
CNS toxicity and CSF pharmacokinetics of intraventricular DFMO and MGBG in beagle dogs (2004) (7)
Changes in electrolytes, pH, and pressure of blood perfusing isolated dog brain. (1967) (7)
Evaluation of misonidazole peripheral neurotoxicity in rats by analysis of nerve trains evoked response. (1982) (7)
RATIONALE FOR AND EXPERIENCE WITH CLINICAL TRIALS OF HALOGENATED PYRIMIDINES IN MALIGNANT GLIOMAS: THE UCSF/NCOG EXPERIENCE (1992) (7)
Uptake and distribution of 3h-methotrexate by the murine ependymo- blastoma. (1972) (6)
Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation. (1979) (6)
Chemotherapeutic approaches to brain tumors (1982) (6)
Stability of carmustine for topical application. (1982) (6)
Phase III Randomized Study of Postradiotherapy Chemotherapy with a-Difluoromethylornithine-Procarbazine , N-( 2-Chloroethyl )-N *-cyclohexyl-N-nitrosurea , Vincristine ( DFMO-PCV ) Versus PCV for Glioblastoma Multiforme 1 (2000) (6)
Phase III Randomized Study of Postradiotherapy Chemotherapy with Combination-Difluoromethylornithine-PCV versus PCV for Anaplastic Gliomas 1 (2003) (6)
Phase II study of spirohydantoin mustard for the treatment of recurrent malignant gliomas. (1987) (6)
l-fucose labeling of brain tumors in rats (1986) (6)
Peripheral nerve segmental demyelination induced by intraneural diphtheria toxin injection. Sodium Na 24 and carbon 14-labeled inulin kinetics in diphtheria toxin-injected nerve and the effect of hydrocortisone. (1974) (6)
Brain, CSF, and tumor pharmacokinetics of alpha-difluoromethylornithine in rats and dogs. (1983) (6)
Clinical Correlations of Cerebrospinal Fluid Polyamine Levels (1983) (6)
Resistance of Brain Tumours to Chemotherapy: Preliminary Studies of Rat and Human Tumours * (1982) (6)
Genetic Polymorphisms in Glutathione S-Transferaset and 0, N-Acetyltransferase, and CYPJA1 and Risk of Gliomas' (1998) (6)
Comparison of 1- and 2-hr delayed brain scans in patients undergoing chemotherapy for primary brain tumors. (1977) (6)
Inhibitors of protein tyrosine kinases (1995) (5)
Hyperfractionated radiation therapy for brain stem gliomas in children and adults (1991) (5)
A phase II study of temozolomide plus pegylated interferon alfa-2b for recurrent anaplastic glioma and glioblastoma multiforme (2005) (5)
Enhancement of apoptosis in irradiated glioblastoma cells by pentoxifylline. (1997) (5)
Lipid peroxidation does not appear to be a factor in late radiation injury of the cervical spinal cord of rats. (1993) (5)
Chemoradiation in brain tumors: assets vs. adverse effects. (1989) (5)
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. (2020) (5)
Pharmacokinetic approaches to drug distribution in the cerebrospinal fluid based on ventricular administration in beagle dogs (1985) (5)
Protein-tyrosine kinase activity and pp60v-src expression in whole cells measured by flow cytometry. (1988) (4)
Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience (2012) (4)
Are gliomas preventable (2007) (4)
A compartmental analysis of 24 Na kinetics in rat cerebrum, sciatic nerve and cerebrospinal fluid. (1972) (4)
Phase II trial of thalidomide in combination with irinotecan in adults with recurrent glioblastoma multiforme (2005) (4)
Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction. (1993) (4)
Attenuation of WAF 1 / Cip 1 Expression by an Antisense Adenovirus Expression Vector Sensitizes Glioblastoma Cells to Apoptosis Induced by Chemotherapeutic Agents 1 , 3-Bis ( 2-chloroethyl )-1-nitrosourea and Cisplatin 1 (1998) (4)
Evaluation of desmethylmisonidazole-induced neurotoxicity in the rat using brainstem auditory evoked potentials. (1984) (3)
Are gliomas preventable? (2007) (3)
Pharmacological principles derived from a monkey brain-tumor model (1977) (3)
Melding a New 3-Dimensional Agarose Colony Assay with the Emax Model to Determine the Effects of Drug Combinations on Cancer Cells (2009) (3)
Detection ofp53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction (1993) (3)
Kinetics and distribution of tritiated putrescine in the domestic cat. (1979) (3)
Factors Influencing the Survival of Rat Brain Tumor Cells after in Vitro Treatment with 1 , 3-Bis ( 2-chloroethyl )-1 (3)
Evaluation of bromodeoxyuridine in glioblastoma multiforme: An NCCC phase II study (1990) (3)
Drug discovery in neuro-oncology: challenges in the path forward. (2018) (3)
Stereotaxic interstitial iodine-125 “boost” in the initial management of malignant gliomas (1990) (3)
Phase I study of vorinostat combined with isotretinoin and temozolomide in adults with recurrent malignant gliomas. (2015) (2)
Molecular pathogenesis and management of gliomas (1993) (2)
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV. (2015) (2)
Misonidazole neurotoxicity in rats: Part II. Effect of pre- and intermittent treatment with pentobarbital on misonidazole neurotoxicity in the rat. (1984) (2)
Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital “Flipbooks” to Control Systems Theory (2022) (2)
Lysate array analyses of signal transduction inhibitors in tumor cell lines (2006) (2)
A frequent polymorphism in exon 1 of the p16/CDKN2 gene. (1995) (2)
Chemical Ionization Techniques for the Analysis of Labile Compounds: 1,3-bis-(2-chloroethyl)-1-nitrosourea Plasma Clearance and Degradation (1978) (2)
Randomized phase II 8-arm factorial study of adjuvant dose-dense (dd) temozolomide (TMZ) with permutations of thalidomide (Thal), isotretinoin (CRA), and/or celecoxib (Cel) for newly diagnosed glioblastoma (GBM). (2012) (2)
Phase II study of the combination of thalidomide and irinotecan in patients with recurrent anaplastic gliomas not on enzyme inducing anticonvulsants. (2006) (2)
Discovery, development, and testing of substrates and inhibitors of pp60c-SRC (1995) (2)
STELLAR: A phase 3, randomized, open-label study of eflornithine with lomustine vs lomustine for patients with first recurrence of anaplastic astrocytoma after RT and adjuvant temozolomide. (2017) (1)
Scientific Program 20th Annual Meeting of the American Society of Pediatric Neurosurgeons (1996) (1)
In Vitro Cytotoxic Effects of Dibromodulcitol in 9L Rat Brain Tumor Cells (1986) (1)
SYMPOSIUM ON THE PRINCIPLES OF RADIATION RESEARCH APPLIED TO ENVIRONMENTAL AGENTS The Concept of Drug Dose for in Vitro Studies with Chemotherapeutic Agentsl (1978) (1)
Medical and Neuro-Oncology (2010) (1)
Final results of a phase I trial with the novel anthracycline derivative RTA 744 in patients with primary brain tumors (2007) (1)
Brain and nervous system Editorial overview (1990) (1)
Levels of N 7-( 2-hydroxyethyl ) guanine as a molecular dosimeter of drug delivery to human brain tumors 1 (2005) (1)
Controversies in Neuro-Oncology (Avastin and Malignant Gliomas) (2011) (1)
Radiation necrosis of central nervous system studied by PET (1985) (1)
How far will the Voyager® take us? (2019) (1)
Misonidazole neurotoxicity in rats: Part I (1984) (1)
10 – CLINICAL CHARACTERISTICS OF CANCER IN THE BRAIN AND SPINAL CORD (1981) (1)
Medical and Neuro-Oncology (2010) (1)
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. (2010) (1)
Study design considerations for phase II trials of anaplastic gliomas and its impact on phase III survival studies. (2006) (1)
Overexpressed WAFl / Cipl Renders Glioblastoma Cells Resistant to Chemotherapy Agents l , 3-Bis ( 2-chloroethyl )-l-nitrosourea and Cisplatin 1 (2006) (1)
The pathophysiology of obstructive hydrocephalus in the monkey. (1970) (1)
Inhibition of adenylate cyclase by antitumor agent tetraplatin (1990) (1)
A PHASE II STUDY OF riFN–β+/- cRA IN RECURRENT GLIOMAS (1994) (1)
Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures (2012) (1)
Erratum: A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo (Oncogene (2000) 19 (2-12)) (2000) (1)
Present and future prospects for the chemotherapy of gliomas (1994) (1)
Subject Index Vol. 8, 1981 (1981) (0)
P15 02 MP – HYPERFRACTIONATED RADIATION THERAPY FOR BRAIN STEM GLIOMAS IN CHILDREN AND IN ADULTS (1991) (0)
Patients Undergoing Chemotherapy for Primary Brain Tumors (2006) (0)
Multicenter P hase I I T rial o f T emozolomide i n P atients With A naplastic A strocytoma o r A naplastic Oligoastrocytoma a t F irst R elapse (1999) (0)
Experimental Tumors of the Central Nervous System (1978) (0)
Lenalidomide and irinotecan in adults with recurrent malignant gliomas: Phase I results of the phase I/II trial. (2012) (0)
Book Review:Fluid Environment of the Brain. Helen F. Cserr, Joseph D. Fenstermacher, Vladimir Fencl (1976) (0)
MR imaging spectrum of radiation therapy- andchemotherapy-induced necrosis of the brain after treatmentof malignant gliomas (2008) (0)
Treatment of anaplastic oligodendrogliomas: should resources be used to codify the old or to create the new? (2013) (0)
Abstracts for the Tenth International Conference on Brain Tumour Research and Therapy (2005) (0)
MENTAL DYSFUNCTION AFTER BRAIN IRRADIATION. Authors' reply (2008) (0)
Protein-Tyrosine Kinase Activity and pp 60 " ~ ircExpression in Whole Cells Measured by Flow Cytometry 1 (2006) (0)
Contents, Vol. 8, 1981 (1981) (0)
CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
Abstracts for the Tenth International Conference on Brain Tumour Research and Therapy (2005) (0)
Phase I I T rial o f t he A ntiangiogenic A gent T halidomide i n Patients W ith R ecurrent H igh-Grade G liomas (2000) (0)
CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
Glioma treatment, radionecrosis, and growth factors. Author's reply (2003) (0)
CHAPTER 33 – Neurotoxic Effects of Pharmaceutical Agents IV: Cancer Chemotherapeutic Agents (2009) (0)
The Uptake , Distribution , and Antitumor Activity of 1-( 2-Chloroethyl } 3 cyc 1 oh @ exy 1 â€ ” 1-nitrosourea in the Murine Glioma (2006) (0)
Part II Primary Central Nervous System Tumors (2002) (0)
ACTR-41. AN ARGUMENT THAT MORE ADJUVANT TEMOZOLOMIDE THERAPY IS BETTER FOR GLIOMA PATIENTS (2019) (0)
Phase II study of TPDCV in childhood. Medulloblastoma, anaplastic ependymoma, and highgrade astrocytomas (1998) (0)
Brain and nervous system. (1994) (0)
Avastin and Malignant Gliomas (2010) (0)
Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients (Expert Review of Anticancer Therapy (2008) 8, 5, (733-741)) (2011) (0)
Book Reviews (2003) (0)
147 Accelerated radiation with concomitant carboplatin for glioblastoma multiforme (1995) (0)
Ask the Experts: How best to treat recurrent glioma. (2012) (0)
Phase II Tria l o f the Ant iangiogenic Agent Thal idomide in Pat ients With Recurrent High-Grade Gl iomas (2000) (0)
Abstract CT136: STELLAR: A phase 3, randomized, open-label study to evaluate the efficacy and safety of eflornithine with lomustine compared to lomustine alone in patients with anaplastic astrocytoma that progress/recur after irradiation and adjuvant temozolomide chemotherapy (2017) (0)
Misonidazole neurotoxicity in rats: Part 11 (2004) (0)
Medulloblastoma: Results with combined modality therapy (1989) (0)
NEUROIMAGING IN NEURO-ONCOLOGY (2008) (0)
Nitrosoureas: Clinical and Experimental Considerations in the Treatment of Brain Tumors (1976) (0)
Inhibition of adenylate cyclase by tetraplatin (1991) (0)
Central Nervous System Toxicity and Cerebrospinal Fluid Pharmacokinetics of Intraventricularly Administered Bleomycin in Beagles1 (2006) (0)
+++Clinical toxicology and pharmacology of misonidazole- an hypoxic cell radiosensitizer (1978) (0)
S17 06 TA – PROMISE AND PROBLEMS IN THE USE OF HALOGENATED PYRIMIDINES IN THE TREATMENT OF MALIGNANT GLIOMAS (1991) (0)
Diagnosis and treatment of metastatic brain cancer: Comments (2005) (0)
Effect of eflornithine on mutation frequency in temozolomide-treated U87MG cells (2020) (0)
Treatment of malignant gliomas with irradiation and misonidazole (1979) (0)
Abstracts of the Second International Symposium on Biology of Brain Tumor (2004) (0)
Outcomes a nd P rognostic F actors i n R ecurrent G lioma Patients E nrolled O nto P hase I I C linical T rials (1999) (0)
Multimodality management (surgery, radiation, radiosensitization and chemotherapy) of malignant gliomas (1978) (0)
129 POSTER Preliminary results of a accelerated dose escalation phase I trial with a novel anthracycline derivative (RTA-744) in patients with primary brain tumors (2006) (0)
Chemotherapy as first line treatment for oligodendroglioma (2008) (0)
A phase I study using I-131 NaI to treat leptomeningeal metastases via intraventricular injection (2008) (0)
Erratum: Corrigendum (2010) (0)
ON THE CORROSIVITY OF CHLORORGANIC SOLVENTS (1997) (0)
Effect of misonidazole, and pre- and intermittent treatment with pentobarbital on misonidazole, on auditory evoked potentials in the rat (1984) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Victor Alan Levin?

Victor Alan Levin is affiliated with the following schools:

Victor Alan Levin's Academic­Influence.com Rankings

Victor Alan Levin's Degrees

Why Is Victor Alan Levin Influential?

Victor Alan Levin's Published Works

Published Works

What Schools Are Affiliated With Victor Alan Levin?

Victor Alan Levin's AcademicInfluence.com Rankings